I Cookies vengono usati per fornirti un servizio migliore. Proseguendo con la navigazione, acconsenti al loro utilizzo. Per negare il consenso o eliminarli dal tuo browser visita www.aboutcookies.org. Per maggiori informazioni leggi l'informativa.
It took ten years of immersion in the world of cancer research to produce the book that won Clifton Leaf a Best Cancer Reporter Lifetime Achievement award. But it started from a simple question: how do claims about winning the war on cancer square with a failure to cut death rates?
Early detection, disease prognosis, a guide to treatment, a key to unlock the secrets of how cancers evolve. Researchers have high hopes for what they can learn from the biological detritus shed by primary tumours and metastases.
Our new vocabulary Â– gene, genome, molecular, targeted, personalised Â– no longer inspires the confidence it once did, and as the cancer community prepares to gather at the 18th ECCO - 40th ESMO European Cancer Congress in Vienna, there is a real sense of uncertainty about where the next major progress will come from, writes Alberto Costa in this editorial.
Denis Lacombe quietly orchestrating the clinical research revolution
The scientific complexity and economic cost of developing new cancer therapies demand a level of collaboration and sharing that takes both industry and academia well beyond their comfort zones. EORTC head Denis Lacombe believes he has the passion and the vision to help make it happen.